ABOS · Acumen Pharmaceuticals, Inc.
$2.67
+0.12 (+4.71%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we expect that our current balance of cash and cash equivalents and marketable securities will fund our operations into early 2027, but we believe it will not be enough to fund our operations for at least 12 months from the date of issuance of our financial statements included in this Quarterly Report on Form 10-Q. Our cash forecast contains estimates and assumptions related to our ongoing clinical trial and other research and development expenses, and we cannot predict the amount or timing of all expenditures with certainty. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$193.09M
Shares
72.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.67
Open$2.51
Day$2.45–2.70
52W close$1.23–3.37
Avg vol 30d354K
Short int3.4M · 4.7% float · 9.5d
Short vol64%
Last earningsAug 12, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
+13%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
67%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+3%
trailing
YTD return
+27%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +30 funds added
Insider flow
Distributing
Net -$89.5K over 90 days · 100% sells
Short interest
Rising
4.66% of float · ▲ +19.6% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
−17%
Y/Y
Balance sheet
$22.8M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
67%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +30 funds added
Insider flow
Distributing
Net -$89.5K over 90 days · 100% sells
Short interest
Rising
4.66% of float · ▲ +19.6% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 67%
Range high $3
vs 200-day avg +13%
vs 50-day avg +13%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $128.4M | Q1 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABOS
this stock
Acumen Pharmaceuticals, Inc.
|
$193.09M | +26.5% | — | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABOS | +9.4% | +18.7% | +3.5% | +24.2% | +26.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +9.0% | +14.2% | -10.3% | +20.3% | +12.7% |
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
93 filings
93 filers
Visit website
Investor relations